Hudson Bay Capital Management
NKTR icon

Hudson Bay Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Hudson Bay Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,333
Closed -$270K – 1395
2022
Q1 		$270K Buy
3,333
+1,326
+66% +$196K ﹤0.01% 901
2021
Q4 		$407K Buy
+2,007
New +$435K ﹤0.01% 869

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hudson Bay Capital Management's NKTR Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Nektar Therapeutics (NKTR) stake by 83% in Q1 2026, selling an estimated $2.81M and leaving 10,332 shares worth $743K. The position accounts for ﹤0.01% of the portfolio, ranked #925.

Hudson Bay Capital Management first reported a position in NKTR in Q2 2018 and has held it in 16 quarters since. The position peaked at $6.13M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Hudson Bay Capital Management held 10,332 shares of Nektar Therapeutics worth $743K as of Q1 2026.
  • Hudson Bay Capital Management sold 49,359 Nektar Therapeutics shares in Q1 2026, an estimated $2.81M.
  • Nektar Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #925 holding.
  • Hudson Bay Capital Management first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 16 quarters since.
  • Hudson Bay Capital Management's Nektar Therapeutics position peaked at $6.13M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.